Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
Journal Title
Journal of Nuclear Medicine
Publication Type
Online publication before print
Abstract
[(177)Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [(177)Lu]Lu-DOTATATE but has not, to our knowledge, yet been reported after [(177)Lu]Lu-PSMA. This case series describes 5 patients with mCRPC who developed t-MN after [(177)Lu]Lu-PSMA at our institution. Methods: In this single-center retrospective analysis, we reviewed all patients with mCRPC treated with [(177)Lu]Lu-PSMA. Patients who developed biopsy-proven t-MN during or after [(177)Lu]Lu-PSMA treatments are summarized with descriptive statistics. Results: From August 26, 2015, to December 31, 2022, 5 of 381 (1.3%) patients treated with [(177)Lu]Lu-PSMA were subsequently diagnosed with t-MN. Their median age at cycle 1 (C1) was 78 y (range, 65-80 y). The median time from C1 to t-MN diagnosis was 33.6 mo (range, 6.0-58.8 mo). Previous treatments included docetaxel (n = 5), external-beam radiotherapy to metastases (n = 5), abiraterone (n = 4), enzalutamide (n = 3), and cabazitaxel (n = 3). On PSMA PET/CT, 4 (80%) patients had predominantly bone metastases and 1 (20%) had predominantly nodal metastases. They were treated with [(177)Lu]Lu-PSMA-617 (n = 3) or [(177)Lu]Lu-PSMA-I&T (n = 2). A median of 7 cycles (range, 4-12 cycles) of [(177)Lu]Lu-PSMA was administered, with a median total cumulative activity of 49.2 GBq (range, 31.3-79.0 GBq). Prostate-specific antigen reduction of at least 50% or at least 80% from baseline was seen in 5 (100%) and 4 (80%), respectively. All had prostate-specific antigen progression preceding t-MN diagnosis. t-MN diagnosis included myelodysplastic syndrome with single-lineage dysplasia (n = 2), myelodysplastic syndrome with excess blasts 1 (n = 1), acute promyelocytic leukemia (n = 1), and acute myeloid leukemia (n = 1). At t-MN diagnosis, all patients presented with at least grade 2 cytopenia, involving one or more blood cell lines. Marrow genetic analysis revealed unfavorable karyotypes or mutations in all patients. Most patients received supportive care after t-MN diagnosis. Survival was 8.1, 31.3, 43.0, 56.0, and 60.4 mo from C1 and 1.8, 2.1, 6.8, 10.3, and 12.4 mo from t-MN diagnosis. Conclusion: In the mCRPC population after chemotherapy, we describe a low incidence of t-MN after [(177)Lu]Lu-PSMA therapy. Ongoing follow-up is necessary to further define the true incidence of t-MN or other unexpected delayed toxicities, particularly with earlier use of [(177)Lu]Lu-PSMA in the disease course.
Keywords
[177Lu]Lu-PSMA; mCRPC; t-MN
Department(s)
Cancer Imaging; Medical Oncology; Laboratory Research
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-03-14 07:06:34
Last Modified: 2025-03-14 07:08:56

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙